CPT 0283U: Versiti VWD Type 2B Evaluation, Plasma Assay

CPT code 0283U designates the Versiti™ VWD Type 2B Evaluation, a specialized plasma-based laboratory test that assesses platelet binding and von Willebrand factor multimer patterns to differentiate VWD Type 2B from other von Willebrand disease subtypes. Introduced effective October 1, 2021, the code captures a single-company diagnostic assay that has implications for accurate classification of a rare but clinically significant bleeding disorder. Nationally, precise coding of such assays matters for claim adjudication, coverage determinations, and tracking utilization of emerging or proprietary diagnostics.

Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, the typical laboratory setting where it is performed, and the potential payer landscape relevant to coverage and billing. The publication outlines coding context, effective date, and what to expect in payer interactions—such as the presence of a single-source proprietary assay—and summarizes areas where data were not provided.

This document is written for a national audience and is intended to inform billing staff, laboratory managers, and policy analysts about the code's clinical role, administrative classification, and the payer environment to consider when submitting or reviewing claims related to specialized VWD diagnostic testing.

Billing Code Overview

CPT code 0283U is a laboratory assay code established for the Versiti™ VWD Type 2B Evaluation performed by Versiti™ Diagnostic Laboratories on a plasma specimen. The test evaluates platelet binding and multimer levels to differentiate subtypes of von Willebrand disease (VWD) Type 2B, supporting diagnostic classification and management decisions.

Service type: Laboratory diagnostic test — specialized coagulation/hematology assay

Typical site of service: Independent diagnostic laboratory or hospital laboratory that receives plasma specimens

Data not available in the input.

Clinical Context

A 28-year-old woman with a history of easy bruising, mucosal bleeding, and a family history of von Willebrand disease is referred to a hematology clinic. Prior screening tests show low von Willebrand factor antigen and abnormal ristocetin cofactor activity with suspected qualitative VWF abnormality. The clinician orders the Versiti™ VWD Type 2B Evaluation (0283U) on a plasma specimen to assess platelet binding and VWF multimer distribution to differentiate Type 2B VWD from other VWD subtypes and platelet-type (pseudo) von Willebrand disease. Blood is drawn in the outpatient phlebotomy area or specialty laboratory, labeled, and shipped to Versiti™ Diagnostic Laboratories under required specimen handling conditions. Results are reviewed by the hematologist; findings of enhanced platelet binding and loss of high-molecular-weight multimers support a diagnosis of Type 2B VWD and guide management decisions such as avoiding platelet-activating therapies, considering desmopressin testing responses, and perioperative hemostatic planning. Typical sites of service include outpatient specialty hematology clinics, hospital outpatient labs, and reference laboratory collection centers.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when only the interpreting physician's professional component is billed separately from the technical lab work (rare for reference lab send-outs).

Taxonomy Code	Specialty	Notes
2080P0207X	Hematology	Hematologists order, interpret VWD subtype evaluations.
207RC0000X	Pathology	Clinical pathologists or laboratory directors oversee testing quality at reference labs.
207K00000X	Clinical Laboratory	Clinical laboratory specialists manage specimen processing and testing workflows.
208D00000X	Pediatrics	Pediatric hematologists evaluate congenital bleeding disorders in children.
2085R0201X	Thrombosis/Hemostasis	Subspecialists focusing on coagulation disorders interpret complex VWD testing.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`D68.0`	von Willebrand disease	Primary indication for VWD subtype testing to characterize disease type and guide therapy.
`R58`	Hemorrhage, not elsewhere classified	Presentation of significant bleeding prompting coagulation and VWD workup.
`R31.0`	Gross hematuria	Mucosal bleeding manifestation that may lead to evaluation for VWD.
`R02`	Gangrene (included for completeness)	Data not applicable — Data not available in the input.
`D69.5`	Secondary thrombocytopenia	Differential consideration when platelet counts or function alter bleeding presentation.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`0283U`	Versiti™ VWD Type 2B Evaluation — platelet binding and multimer analysis on plasma	Primary service code describing the specialized reference laboratory assay to evaluate Type 2B VWD.
`85302`	Prothrombin time (PT); plasma or whole blood	Common baseline coagulation screen often obtained before specialized VWD testing.
`85320`	Thrombin time (TT)	Ancillary coagulation test that may be part of comprehensive hemostasis evaluation.
`85367`	Platelet function screening tests (e.g., platelet function analysis)	Performed to assess platelet function when platelet-type VWD is considered in differential.
`82784`	Von Willebrand factor antigen	Quantifies VWF antigen level and is typically ordered alongside subtype-specific testing.
`85379`	von Willebrand factor multimers analysis (non-specific lab code)	Traditional multimer analysis may be performed or referenced alongside the specialized assay.

OpenPayer

Summary & Overview